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ABSTRACT 
Introduction Vitiligo is a common acquired, idiopathic skin disorder, this study was conducted to evaluate the effectiveness of Ginkgo biloba in 
patients with vitiligo. Material and Methods Fifty persons were included, twelve patients received Ginkgo biloba capsule (75mg) twice daily 
compared with twelve patients received placebo capsule for 8 weeks at Al-Kadhimyia Teaching Hospital. Twenty six healthy volunteers considered 
as control. Patient's history was taken and measurement of neutrophils percentage, serum Glutathione (Elleman methods), Malonialdehyde (Stocks 
and Dormandy methods), Interlukine -6 (Elisa) and Vitiligo area scoring index (VASI) at baseline, 4 and 8 weeks interval, as a parameters to indicate 
the impact of Ginkgo biloba on the disease.  
 Results and discussion showed significant decrease in serum interlukin-6 (S. IL-6) after 4 weeks between Ginkgo biloba group and placebo group. 
No significant difference was found in Neutrophils percent between Ginkgo biloba group and placebo group after 4 and 8 weeks. There was a 
significant increase in serum glutathione (S. GSH) after 4 and 8 weeks in Ginkgo biloba. Serum malondialdehyde (S. MDA) showed no significant 
difference between Ginkgo biloba group and placebo group after 4 and 8 weeks and no changes in VASI were found after 8 weeks between Ginkgo 
biloba and placebo group.  
Conclusion Ginkgo biloba may has good activity in vitiligo treatment.  
Keywords: Ginkgo biloba, vitiligo, antioxidant.  
INTRODUCTION 
Vitiligo is a common acquired, idiopathic skin disorder that 
characterized by one or more patches of depigmented skin because 
of loss of cutaneous melanocytes [1]. Vitiligo occurs in 1% of the 
world’s population [2] and affects all races [3]. Different studies 
suggest that there are some genetic mechanisms that involved in the 
etiology of vitiligo [4], with a positive family history in at least 30% 
of cases [5]. The disease is unpredictable, and is often associated 
with periods of remission and exacerbation [6]. An evidence for 
increased oxidative stress in the entire epidermis of vitiligo patients 
is reported. [7]. Reactive oxygen species are formed always by many 
biological processes, and may be considered as a measure of 
biological inefficiency since they are formed by electron leakage 
from the membranes and inadequately coupled reactions [8]. 
Dammak and his research assistants found that antioxidant system 
are markedly decreased with increased oxidative stress in the blood 
of active vitiligo patients [9].  Khan and his assistants discovered 
oxidative system balance changing in vitiligo patients, that there are 
significant increased levels of malondialdehyde (MDA) and 
significant decreased levels of Superoxide dismutase (SOD), 
Glutathione peroxidase (GPx), vitamins C and E and total antioxidant 
activity in vitiligo patients when compared with controls [10]. 
Ginkgo biloba is a small tree native to China, but widely planted as an 
ornamental, and cultivated for health use in Korea, France, and the 
United States. [11]. Ginkgo biloba leaf extract was investigated for 
active constituents by Craig and Stitzel, they found that it contains 
24% flavone glycosides and 6% terpene lactones [12].  
Parsad points out that Ginkgo is known to have anti-inflammatory an 
immune-modulator, and antioxidant properties [13], thus 
potentially may affecting the oxidative stress mechanisms of vitiligo. 
The constituents of Ginkgo biloba have been shown to decrease 
oxidative stress in macrophages and endothelial cells [14]. This 
study is designed to evaluate the effectiveness of systemic Ginkgo 
biloba in patients with vitiligo and to measure the inflammatory 
parameters (Interleukin -6) and oxidative stress parameters 
(glutathione and malondialdehyde) in patients with vitiligo in 
comparison with healthy volunteers.  
 
 
Patients and Methods 
A prospective, randomized, single blind and placebo controlled 
designed was conducted in this study. The study was done in the 
Department of Dermatology and Venereology, Al-Kadhimyia 
Teaching Hospital between November 2011 and March 2012. The 
total number of persons sharing in this study was 52. Fifty persons 
were continued their treatment course successfully while two 
persons were unable to do so. All included subjects have consented 
to be enrolled in this study and approval of college council at AL-
Nahrain Medical College was taken under order number 1093 in 
1/12/2011. All patients were subjected to detailed examination 
including the general, physical and mainly the skin examination. The 
diagnosis was made clinically by dermatologist. For all the patients 
at the initial visit, baseline characteristics had been made and 
involve age, sex, medical history, family history and drug allergy. 
Patients with a new onset (less than 2 years), localized small patches 
vitiligo of both sexes the affected body surface area of 10-20% with 
age range 18-58 years were included in this study. Along the course 
of treatment, each patient should satisfy three visits at 0, 4 and 
8weeks. In each visit, the assessment of response of vitiligo lesion 
toward treatment was performed by using VASI (Vitiligo Area 
Scoring Index) calculation which is a quantitative parametric score. 
The total body VASI is calculated using a formula that includes 
contributions from all body regions [15]. 
VASI = All Body Sites 
 [Hand Units] × Residual Depigmentation [15] 
A blood sample (5 ml) was obtained to determine Neutrophils 
percent, Serum Glutathione (S. GSH) ( It is based on the reaction of 
aliphatic compounds with dithio 2-nitrobenzoic acid at ph 8.0. to 
give p-nitro thiolphenol anion which is highly, colored at 412nm) 
[16], serum Malonialdehyde (S. MDA) ( its measurement is based on 
the reaction of thiobarbituric acid with MDA forming a pink- colored 
adduct that its light absorbance measured at 535 nm) [17], and 
Interlukine -6 (IL-6) (Using ELISA, the microtiter plate provided in  
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the kit has been pre-coated with an antibody specific to IL-6). The  
patients were allocated into two groups and all the patients were 
given Vaseline and asked to apply it topically two times daily. 
Group I: Included 12 patients (7 females and 5 males) were given 
Ginkgo biloba 1 capsule (75mg) two times daily orally with food for 
8 weeks. 
Group II: Included 12 patients (8 females and 4 males) were given 
sucrose as placebo capsule two times daily orally with food for 8 
weeks. 
Group III: Include 26 healthy subjects (17 females and 9 males) 
without treatment. 
The experiment design used for these studies was Rationalized 
Complete Block Design (RCBD). The results were reported as means 
± standard deviation (SD). 
Unpaired t-test and Wilcoxon Mann –Whitney test for the 
significance of difference done and was considered statistically 
significant if the P value was less or equal to 0.05 and highly 
significant if the P value was less or equal to 0.001 [18]; [19]. 
RESULTS 
 Table (1) shows the descriptive parameters of healthy subjects and 
patients in this study. 
Table1: Descriptive parameters of healthy and patients with vitiligo 
Parameters patients(n=24) control group(n=26) 











Smoking Yes/No 5/19 20.83/79.17 4/22 15.38/84.62 







Family history Yes/No 12/12 50/50 0/26 0/100 
Drug allergy Yes/No 0/24 0/100 0/26 0/100 
Table (2) shows a Significant difference in Neutrophils percent in 
patients with vitiligo in comparison with healthy group, while high 
significant were founded in IL-6, S. GSH and S. MDA in patients with 
vitiligo in comparison with healthy group. 
Table2: Comparison between healthy volunteers and patients 
with vitiligo in relation to Neutrophils, IL-6, S. GSH, and S. MDA. 








baseline   
56.74±6.15 63.58±9.73 0.0042* 
S. IL-6 (pg/ml) 
baseline 
0.93±0.13 3.41±1.65 < 
0.0001** 
S. GSH (mmol/l) 
baseline 




1.9±0.27 2.64±0.64 < 
0.0001** 
 * Denote significant difference at P value ≤ 0.05, ** Denote high 
significant difference at P value ≤ 0.001     
Table (3) and (4) indicate that both treated groups are comparable 
with no significant difference in the parameters at baseline (before 
treatments) .  
Table 3:  The Effect of Ginkgo biloba on Neutrophils, S. IL-6, S. 
GSH and S. MDA concentration in patient with vitiligo in 
comparison with placebo-treated group 





Neutrophils % baseline  59.94±11.31 61.83±4.23 0.5945 
Neutrophils % 4wk  60.46±11.19 59.97±6.63 0.897 
Neutrophils % 8wk  61.23±10.95 59.78±6.66 0.6973 
S. IL-6 (pg/ml) baseline 3.52±1.71 2.31±1.39 0.0693 
S. IL-6 (pg/ml) 4wk 3.47±1.64 0.91±1.12  
0.0002** 
S. GSH (mmol/l) 
baseline 
1.43±0.22 1.62±0.38 0.1598 
S. GSH (mmol/l) 4wk 1.44±0.23 1.72±0.39 0.0391* 
S. GSH (mmol/l) 8wk 1.44±0.23 1.81±0.4 0.0123* 
S. MDA(mmol/l) 
baseline 
2.58±0.21 2.73±0.16 0.0725 
S. MDA(mmol/l) 4wk 2.58±0.2 2.42±0.4 0.2144 
S. MDA(mmol/l) 8wk 2.65±0.24 2.38±0.38 0.0508 
* Denote significant difference at P value ≤ 0.05, ** Denote high 
significant difference at P value ≤ 0.001 
Table 4:  Effects of Ginkgo biloba on clinical feature (VASI score) 
in patients with vitiligo in comparison with placebo-treated 
patients 
Parameters Placebo  
(n=12) 
mean±SD 




VASI baseline 3.75±2.81 6.42±4.08 0.069 
VASI 4wk 3.75±2.81 6.42±4.08 0.069 
VASI 8wk 3.88±2.77 6.17±4.27 0.126 
Table (3) showed that there were no significant difference in 
Neutrophils percent between Ginkgo biloba group and placebo group 
at baseline, 4 weeks and 8 weeks; Table (3) showed high significant 
decrease in S. IL-6 was found after 4 weeks between Ginkgo biloba 
group and placebo group and there was a significant increase in S. 
GSH after 4 and 8 weeks in Ginkgo biloba group as shown in Table 
(3), while Table (3) showed the measurement of S. MDA indicate no 
significant difference between Ginkgo biloba group and placebo 
group after 4 and 8 weeks was recorded. Table (4) showed the 
clinical parameters, no significant difference in VASI between Ginkgo 
biloba group and placebo group after 4 and 8 weeks was found. 
DISCUSSION  
Vitiligo is an acquired pigmentary skin disease characterized by 
normal hyperpigmented border that contain inside a depigmented 
white patches [20]. The precise pathogenesis of vitiligo remains 
unknown although genetic, immune and oxidative stress 
mechanisms had been suggested recently [21]. In the current study 
significant increase in Neutrophils is recorded in patients with 
vitiligo and this is disagreeing with Aksoy et al. [22]. In agreement 
with the in vitro study, in vivo studies showed that Tissue necrosis 
factor- alpha, IL (interlukine)-la, IL-18, IL-6, IL-8, growth related 
protein a (GRO a), macrophage inflammatory protein (MCP) -1 and 
IL-1 receptor antagonist (IL-1 Ra), affect the  inflammation process 
and all of these cytokines are released from Neutrophils . [23]. This 
study showed that the serum level of Interleukin-6 is significantly 
elevated in patients with vitiligo when compared with healthy 
volunteer. This is in agreement with studies data of elevated serum 
level of interleukin-6 in patients with vitiligo [24]; [25], in addition 
to that when perilesional, non-lesion and healthy skin is investigated 
for epidermal IL-6, a significant change was founded in vitiligo skin, 
suggesting that the cytokine production in epidermal surroundings 
may be occurred. [26]. Moreover, IL-6 plays a role in inhibiting 
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melanocyte growth [27]. In a study conducted by Yu et al., [25], Yu 
discovers that IL-6 production of mononuclear cells (MNC) to be 
significantly increased in vitiligo patients. This study showed the 
significant decrease level of GSH in patient with vitiligo in 
comparisons to healthy volunteers and this is agree with the 
reasonable to assertion of Shin et al. [28] that GSH is systemically 
depleted to counter free radicals. Park et al. [29] reported that, 
melanocyte apoptosis is under arrest by glutathione through 
inhibition of dopamine. Glutathione is a constituent of nonenzymatic 
antioxidant system and also it is a substrate for GSHPx. Passi et al. 
[30] showed that the epidermal GSH levels were significantly lower 
in active vitiligo patients when it is compared with controls.  
However the present study did not agree with Ozturk et al. [31] who 
showed that plasma glutathione levels did not change significantly in 
both types of it. Imbalance of Oxidative process can be induced by 
increased reactive oxygen species (ROS) production. Reactive 
oxygen species play an important role in cell signaling, but 
insufficient antioxidant level or increased ROS generation causes 
damage due to increase oxidant/antioxidant ratio. Reactive oxygen 
species can then induce a cytotoxic damage in melanocytes via either 
by initiation of melanocyte apoptosis or by changing melanocytic 
antigens [32]; [33]. Also the high significant increase in serum level 
of MDA in patient with vitiligo in compared to healthy volunteers is 
agree with those of Ozturk et al. [31], who discovered a significant 
increased in MDA, Hydroxyproline and GSHPx  levels in plasma of 
vitiligo patients lead to that H2O2 generate free radicals and 
imbalances in oxidant/antioxidant ratio, which leads to oxidative 
stress, resulting in increased MDA levels, which is lipid peroxidation 
end product. Koca et al. [34] has also reported increased serum MDA 
levels in patients with vitiligo. Similar results have been reported by 
Ines et al. [35]. No Significant difference in Neutrophils in the 
current study is recorded in patients with vitiligo and this is 
agreeing with Aksoy et al. [22]. The current study showed high 
significant decrease in S. IL-6 in Ginkgo biloba treated patients after 
4 weeks. This is in agreement with Ching-Hsiang et al. [15] who 
conclude that Ginkgo biloba extract used for neurological problems 
by down-regulation and suppression of IL-6. It was found in this 
study a significant increase in S. GSH after 4 and 8 weeks in Ginkgo 
biloba treated group, this is agree with Rimbach et al. [36] who 
conclude that when increase the dose of Ginkgo biloba extract, an 
increase in  cellular GSH occurred in a human keratinocyte cell 
culture model, while in this study S. MDA showed no significant 
difference between Ginkgo biloba -treated group and placebo-
treated group after 4 and 8 weeks and this is disagree with Zhou et 
al. [37] who conclude that Ginkgo biloba extract decrease the MDA 
level in trinitrobenzene sulfonic acid-induced colitis in rats in 
relation to increase the dose of Ginkgo biloba extract. Also Thanoon 
et al. [38] reported a significant decrease in serum levels of MDA in 
ischemic stroke patients that received Ginkgo biloba (1500 mg/day) 
for 30 days. The different dose and different pathogenesis use may 
explain the different results. This study found no significant 
difference in VASI between Ginkgo biloba -treated group and 
placebo-treated group after 4 and 8 weeks from starting treatment. 
This result disagree with Szczurko et al. [39] who conclude that the 
total VASI score showed a significant improvement during  12 week. 
This difference is probably due to the fact that in Szczurko et al. [39] 
study continues for 12 week and it is also possible that genetic, 
dietary and social differences between the populations of the two 
studies had an impact on the results. The study concludes that 
Ginkgo biloba may have promising activity in vitiligo remedy. 
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